ICON won the award for a project involving the unexpected, rapid closure of selective populations participating in a mega trial programme consisting of over 19,000 subjects at approximately 900 sites world-wide. The close-out was achieved initially by careful consideration of the regulatory and ethics considerations relating to the closure and subsequently by the careful planning and coordination of activities that were required to achieve a complete and appropriate closure.
Commenting on the award, Ciaran Murray, CEO, ICON plc, said: “We are delighted with the award from Scrip and that our team has been recognised as the industry’s best. The unexpected closure of selective populations in a mega-trial programme is a highly unusual situation which demanded a clear understanding of the regulatory and ethics considerations, a detailed and achievable plan, excellent communication, good leadership and a dedicated, hardworking team. Our team performed this complex task exceptionally and it’s nice to see that their efforts have been recognised.”
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 8,300 employees, operating from 79 locations in 38 countries.
Further information is available at www.iconplc.com
Contact
Yasamin Omoomian
Weber Shandwick
+44 (0)20 7067 0594
